Epstein Secrets

pproximately 50% higher than had been postulated led to a shorter required duration of follow-up to accrue the prespecified number of events." Dr. Sabatine emphasized the importance of aggressive LDL-lowering treatment in the future. "We need to treat LDL cholesterol more aggressively, and now we have a

ply-To: Cardiology Alert <I Email not displaying correctyNiaw it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study. presented at the 2017 American College of Cardiology Scientific Session in Was

pproximately 50% higher than had been postulated led to a shorter required duration of follow-up to accrue the prespecified number of events." Dr. Sabatine emphasized the importance of aggressive LDL-lowering treatment in the future. "We need to treat LDL cholesterol more aggressively, and now we have a

y Alert < EFTA00447987 Entail not displaying coirectly?View it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2017 American College of Cardiology Scientific Session in Was

approximately 50% higher than had been postulated led to a shorter required duration of follow-up to accrue the prespecified number of events' Dr. Sabatine emphasized the importance of aggressive LDL-lowering treatment in the future. "We need to treat LDL cholesterol more aggressively, and now we have a

Reply-To: Cardiology Alert E— ail not displaying conectly?View it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2017 American College of Cardiology Scientific Session in Was